Insulet CEO sees slower growth in 2027, expects rivals to chip away at Omnipod's market share
<?xml encoding="utf-8" ?> Insulet Corp. PODD stock gained Wednesday after the insulin pump maker reported ...
Model output · Signal date 2026-11-06
Insulet Corp (PODD) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
39.0%
Spearman, 357 dates
Market Cap
$10.16B
large-cap · #14 of 60 peers
Summary
Insulet Corp (PODD) stock forecast summary
Our AI scores Insulet Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Insulet Corp is a large-cap company with a market capitalization of $10.16B. It ranks number 14 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For PODD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 48.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PODD included.
Price
PODD price chart and AI forecast
Cross-section · 2026-11-06
How PODD ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Insulet Corp (PODD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | PODD | Rank |
|---|---|---|
| Market Cap | $10.16B | 14/60 |
| P/E Ratio | 21.11x | 20/27 |
| P/B Ratio | 6.43x | 18/55 |
| EPS | $6.94 | – |
| Book Value/Share | $22.77 | – |
| Revenue/Share | $45.98 | – |
| FCF/Share | $3.75 | – |
Profitability & Margins
| Metric | PODD | Rank |
|---|---|---|
| ROE | 27.1% | 4/40 |
| ROA | 12.6% | 6/43 |
| ROIC | 22.6% | 7/54 |
| Gross Margin | 71.9% | 21/54 |
| Operating Margin | 18.4% | 12/55 |
| Net Margin | 13.4% | 10/42 |
| EBT Margin | 17.2% | 12/55 |
| Tax Rate | 21.9% | – |
Financial Health
| Metric | PODD | Rank |
|---|---|---|
| Current Ratio | 2.51x | 40/59 |
| Quick Ratio | 1.83x | 33/55 |
| D/E Ratio | 1.16x | 17/56 |
| Financial Leverage | 2.16x | 17/54 |
| Interest Coverage | 2.9x | 16/50 |
| Working Capital | $1.23B | 9/59 |
Cash Flow
| Metric | PODD | Rank |
|---|---|---|
| Operating Cash Flow | $509M | 12/56 |
| Free Cash Flow | $260M | 12/50 |
| Capital Spending | -$249M | 42/50 |
| OCF Growth YoY | -4.6% | 22/32 |
| FCF Growth YoY | -38.6% | 24/27 |
| FCF/Sales | 8.2% | 21/50 |
| CapEx/Sales | 7.8% | 5/50 |
Operational Efficiency
| Metric | PODD | Rank |
|---|---|---|
| Asset Turnover | 0.93x | 12/52 |
| Receivables Turnover | 4.6x | 44/52 |
| Inventory Turnover | 1.6x | 34/52 |
| Fixed Assets Turnover | 3.5x | 46/54 |
| Days Sales Outstanding | 79 days | 9/52 |
| Days Inventory | 225 days | 19/52 |
| Payables Period | 66 days | 23/47 |
| Cash Conversion Cycle | 238 days | 15/42 |
Income Statement
| Metric | PODD | Rank |
|---|---|---|
| Total Revenue | $3.19B | 12/54 |
| Operating Income | $588M | 11/56 |
| Net Income | $429M | 9/43 |
| R&D Expense | $360M | 8/53 |
| SG&A Expense | $1.34B | 9/54 |
| Cost of Goods Sold | $897M | 14/54 |
Dividend & Shareholder Information
| Metric | PODD | Rank |
|---|---|---|
| Shares Outstanding | 69M | – |
| Net Income Growth | 74.2% | 2/18 |
| EPS Growth | 107.2% | 2/21 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2.04B | 59.8% of assets |
| Cash & Short-term Investments | $584M | 17.1% of assets |
| Accounts Receivable | $689M | 20.2% of assets |
| Inventory | $552M | 16.2% of assets |
| Total Liabilities | $1.84B | 53.8% of assets |
| Short-term Debt | $652M | 19.1% of assets |
Quarterly Financial Reports
PODD quarterly financials and insider trading
Industry Peers · Surgical & Medical Instruments & Apparatus
Insulet Corp (PODD) industry peers
Companies classified under the same SEC industry code as Insulet Corp (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PODD Insulet Corp | $10.16B | |
| SYK Stryker Corp | $127.56B | |
| MMM 3m Co | $95.67B | |
| BSX Boston Scientific Corp | $61.95B | |
| BDX Becton Dickinson & Co | $57.71B | |
| MDLN Medline Inc. | $52.27B | |
| RMD Resmed Inc | $33.10B | |
| DXCM Dexcom Inc | $29.62B | |
| WST West Pharmaceutical Services Inc | $27.85B | |
| SOLV Solventum Corp | $14.84B | |
| BAX Baxter International Inc | $13.34B | |
| GKOS Glaukos Corp | $13.28B | |
| PEN Penumbra Inc | $12.66B | |
| GMED Globus Medical Inc | $10.93B | |
| TFX Teleflex Inc | $6.39B | |
| HAE Haemonetics Corp | $5.46B | |
| MMSI Merit Medical Systems Inc | $5.23B | |
| MMED Minimed Group, Inc. | $4.70B | |
| HTFL Heartflow, Inc. | $4.52B | |
| ICUI Icu Medical Inc/De | $4.30B | |
| PLSE Pulse Biosciences, Inc. | $3.80B | |
| STVN Stevanato Group S.P.A. | $3.71B | |
| ATRC Atricure, Inc. | $2.98B | |
| IRTC Irhythm Holdings, Inc. | $2.97B | |
| UFPT Ufp Technologies Inc | $2.35B | |
| LMAT Lemaitre Vascular Inc | $1.85B | |
| INSP Inspire Medical Systems, Inc. | $1.85B | |
| KMTS Kestra Medical Technologies, Ltd. | $1.72B | |
| NVCR Novocure Ltd | $1.55B | |
| TNDM Tandem Diabetes Care Inc | $1.25B | |
| SGP Spyglass Pharma, Inc. | $1.24B | |
| PRCT Procept Biorobotics Corp | $1.18B | |
| DRTS Alpha Tau Medical Ltd. | $1.17B | |
| ATEC Alphatec Holdings, Inc. | $1.15B | |
| IRMD Iradimed Corp | $1.10B | |
| SIBN Si-Bone, Inc. | $1.09B | |
| IART Integra Lifesciences Holdings Corp | $1.04B | |
| AORT Artivion, Inc. | $985M | |
| BBNX Beta Bionics, Inc. | $854M | |
| KIDS Orthopediatrics Corp | $829M | |
| BVS Bioventus Inc. | $727M | |
| TCMD Tactile Systems Technology Inc | $590M | |
| SGHT Sight Sciences, Inc. | $555M | |
| DCTH Delcath Systems, Inc. | $527M | |
| ANGO Angiodynamics Inc | $493M | |
| RCEL Avita Medical, Inc. | $485M | |
| MDXG Mimedx Group, Inc. | $478M | |
| BWAY Brainsway Ltd. | $437M | |
| NPCE Neuropace Inc | $436M | |
| SSII Ss Innovations International, Inc. | $429M | |
| CERS Cerus Corp | $407M | |
| CARL Carlsmed, Inc. | $396M | |
| MOBI Mobia Medical, Inc. | $373M | |
| EMBC Embecta Corp. | $351M | |
| OBIO Orchestra Biomed Holdings, Inc. | $341M | |
| OFIX Orthofix Medical Inc. | $321M | |
| CLPT Clearpoint Neuro, Inc. | $276M | |
| PROF Profound Medical Corp. | $263M | |
| TMCI Treace Medical Concepts, Inc. | $262M | |
| OSUR Orasure Technologies Inc | $232M |
Where PODD sits on the market map
Industrial Applications and Services · Surgical & Medical Instruments & Apparatus
News
Insulet Corp (PODD) stock news
Insulet: Q3 earnings snapshot
ACTON, Mass. (AP) — ACTON, Mass. (AP) — Insulet Corp. (PODD) on Wednesday reported third-quarter net income of $141.1 million. The Acton, Massachusetts-based company said it had net income of $2.03 ...
Evercore Reiterates Outperform Rating for Insulet Corp. (PODD)
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FAQ
Insulet Corp (PODD) stock forecast FAQ
What is the Insulet Corp (PODD) stock forecast?
Our AI scores Insulet Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Insulet Corp stock predictions?
For PODD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 48.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Insulet Corp forecasts updated?
Insulet Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Insulet Corp's industry peers?
60 issuers in our coverage, PODD included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.